The current consensus is that many factors may converge to cause the motor neuron damage typified by ALS (Rothstein 2009)
34, S82
Wellness clinics offering IV glutathione without individualized prescriptions operate in a regulatory gap the FDA monitors through warning letters but has not systematically shut down
This finding is consistent with prior evidence indicating increased glutamatergic transmission early in the illness but diminished glutamate in older or more functionally impaired cases [29,30,31,32,33,34,35,36,37]
Precision lipidology offers a practical path toward improved risk assessment and individualized therapy, but successful adoption will require standardization, clinician education, equitable access, appropriate reimbursement, and outcome-driven implementation